Genmab — Oktober 2024
-
Min teori er at kursen er blevet gjort købsmoden ift. et købstilbud på Genmab..... I min verden kan en broker lave kortvarige kombi handler køb, salg og short, og lave en nul forretning ud af en faldende kurs - Nok via nogle algoritmer.... Nogen vil straks sige at der er jo ikke nogen særlig short positioner i aktien.... - Nej, det er der ikke for disse handler kommer og går hurtigt... - Med andre ord , den sunde normale kursudvikling bliver smadret..
-
Tisotumab vedotin on the EMA PRAC agenda this week for assessment of the Risk management plan https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-30-september-03-october-2024_en.pdf
-
Det er ren spekulation idet interessen er parkeret og afventende. Muligvis for at bane vejen for købstilbud, som nogle skriver, men mere sandsynligt blot for at skabe grundlag for gevinst, når det vender. For det gør det. Og w vi venter ikke på “alt eller intet” data. De eksisterer ikke i nuværende kurs. Som E L noterer fra Jyske: “på det nuværende kursniveau får investorer hele pipelinen samt nogle af de allerede lancerede produkter gratis”. (link)
-
GEN1042 a few updates in the write up, quite a few more locations turned from Recruiting to Completed, so hopefully they have enough data soon to decide on future plans https://clinicaltrials.gov/study/NCT04083599?tab=history&a=28&b=29#version-content-panel
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind